By 2023, the nasal antihistamines market is projected to attain a value of around USD 2.06 billion, with an expected CAGR of 4.6%. Sales of nasal antihistamines are anticipated to reach a noteworthy USD 3.23 billion by 2033 potentially.
Nasal antihistamines are drugs that function by concentrating on the histamine receptors in cells. In addition to treating seasonal allergies, they treat chronic allergies and other recurrent illnesses. Histamine is an immunological substance that the immune system secretes in reaction to allergens or when histamine-deficient foods are consumed.
On the other hand, some foods may result in an allergic reaction due to an increase in the production of histamine. Histamine causes sneezing, runny nose, watery eyes, discomfort, itching, and redness by attaching to certain receptors in human cells.
The nasal antihistamines market is anticipated to expand favorably over the upcoming years due to the rising incidence of allergies and the increasing demand for efficient nasal allergy relief. The nasal antihistamines industry is projected to grow due to technical development and product innovation, which open up chances for nasal antihistamines manufacturers.
New Frontiers with Nasal Antihistamines
| Attribute | Details |
|---|---|
| Nasal Antihistamines Market CAGR (2023 to 2033) | 4.6% |
| Nasal Antihistamines Market Size - 2023 | USD 2.06 billion |
| Nasal Antihistamines Market Size - 2033 | USD 3.23 billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The nasal antihistamines market grew steadily between 2018 and 2022, led by the rise in allergic rhinitis prevalence and the preference for nasal antihistamines as a preferred therapy.
New formulations with greater potency and a longer half-life have been introduced. Healthcare professionals and people are becoming more knowledgeable about the advantages of nasal antihistamines.
The nasal antihistamines industry is expected to maintain its upward trend between 2023 and 2033.
The development of the nasal antihistamines business is likely to be influenced by elements like growing distribution networks, improvements in medication delivery technology, and partnerships for novel therapeutics. The market growth for nasal antihistamines is fueled by research and development projects looking into the potential uses of nasal antihistamines in different respiratory disorders.
Allergic rhinitis (AR) has increased by 100% in the previous three decades, according to the American College of Allergy, Asthma, and Immunology (ACAAI). More than 40% of the United States and Europe population is allergic to one or more inhalant allergens. Intensifying air pollution and greater sensitization to allergens are two possible explanations for the rising prevalence of AR.
According to epidemiological studies, the prevalence of AR has progressively increased in more developed countries, and it now affects 10% to 40% of adults and 2% to 25% of children worldwide. Similarly, a rising trend of AR has been observed in recent decades, particularly in China, as a result of rapid urbanization, westernized lifestyles, and changed eating choices.
According to FMI, the demand for nasal antihistamines is anticipated to grow steadily over the projection period.
Principal Consultant
In developing countries such as India, China, Brazil, Mexico, and South Africa, a growing demand for generic medical items prompts producers to release effective and conveniently accessible nasal sprays and drops.
Lower pricing and easy availability through medical and pharmaceutical retailers contribute to the high demand for these products. Many nasal antihistamine medicines are being de-patented, providing producers an excellent opportunity to introduce innovative and enhanced nasal antihistamines to the market.
The rising prevalence of respiratory illnesses such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis is likely to fuel nasal antihistamines market expansion.
Pharmaceutical companies' investments in research and development, government campaigns to raise awareness of common health issues, improvements in the global healthcare system can continue to spur nasal antihistamine sales over the forecast period.
Regulatory organizations, including the United States Food and Medication Administration (FDA) and the European Medicines Agency (EMA), can examine nasal medication administration.
Before a product is released to the public, these organizations give guidelines and restrictions. They permit various in vitro test procedures to determine the characteristics of nasal medication products, which must fall within the permissible range specified by such regulatory authorities.
The nasal spray can be developed based on the dose needed of medicinal substances for individuals suffering from nasal or other difficulties. Nasal sprays exhibit several exceptional characteristics, including formulation, manufacturing processes, container closing systems, stability, key step controls, intermediates, and medicinal products. The development of a nasal spray program should take these factors into serious consideration. These modifications may impact the product's capacity to treat patients.
It is more difficult for the manufacturer to obtain regulatory agency approval for a nasal spray product subject to strict rules and regulations. The device's design and use can impact the spray characteristics. It is more difficult to produce nasal spray to conduct these tests to obtain the ideal outcome, an acceptable range specified by the regulatory authority.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Attribute | Details |
|---|---|
| United States Market Share - 2023 | 90.5% |
| United Kingdom Market Share - 2023 | 18.9% |
| China Market CAGR (2023 to 2023) | 6.8% |
| India Market Share - 2023 | 46.7% |
According to estimates, the United States to hold 90.5% of the market share for nasal antihistamines in North America in 2023. The dominance is brought about by increased allergic rhinitis cases among children. It was found that in 2020, allergic rhinitis affected about 21.1% of children. Sales of nasal antihistamines may be driven higher over the evaluation period by the rising use of nasal sprays and the United States’ well-established healthcare system.
The United Kingdom is expected to account for 18.9% of the European nasal antihistamine market by 2023. In the United Kingdom, rising demand for nasal antihistamines can be ascribed to new product launches, partnerships among key market players, technological improvements in the healthcare sector, and increased awareness of the benefits of nasal antihistamines in effectively treating allergic rhinitis.
Throughout the projected period, the East Asia area is anticipated to see a 6.8% CAGR in nasal antihistamine sales in China. In China, the nasal antihistamine market is expected to expand in the next few years. As a result of rising healthcare spending per capita, supportive government policies, the introduction of new products, and rising investment in life science research.
In 2023, India accounted for 46.7% of the overall South Asian nasal antihistamines market. Consumers in India are increasingly using nasal antihistamine therapy to treat allergic rhinitis. New product launches in the country at significantly reduced costs are expected to generate growth prospects for key market participants.
Several Indian populace is paying for healthcare out of pocket, so generic products are favored for their low cost. The aforementioned factors are likely to drive nasal antihistamine sales in India.
| Attribute | Details |
|---|---|
| Nasal Sprays Segment Share | 88% |
| Adult Segment Share | Half of the total |
| Retail Pharmacies Segment Share | 42% |
| Retail Pharmacies Segment CAGR | 4.6% |
In terms of product, the nasal sprays segment may continue to dominate the global nasal antihistamines market in 2023, accounting for almost 88% of the total. Several factors are predicted to keep the demand for nasal sprays strong.
These include the continued prevalence of respiratory disorders such as allergies and sinusitis, improved awareness of nose cleanliness, and the convenience and efficacy of nasal sprays in delivering medication directly to the nasal passages.
In terms of age group, adults may account for more than half of the market share in 2023. This tendency is projected to continue during the projection period.
Adult nasal antihistamine sales may hit unprecedented highs, showing a high demand for allergy treatment. This increase in sales reflects the prevalence of allergic disorders and the growing recognition of nasal antihistamines as an effective treatment for allergy symptoms in the adult population.
Based on distribution channels, the retail pharmacies segment is anticipated to hold 42% of the market share for nasal antihistamines in 2023, with sales increasing at a 4.6% CAGR during the forecast period.
Due to their efficiency in treating allergies and reducing nasal congestion, nasal antihistamine sales through retail pharmacies are anticipated to grow. The demand for these goods is expected to rise as more customers look for relief from allergy symptoms, propelling sales development in this market segment.
The nasal antihistamines industry is moderately competitive, with a few significant companies. The nasal antihistamines manufacturers hope to extend their product portfolios by launching new items.
Aside from that, strategic alliances, mergers, and acquisitions are likely to be profitable growth strategies significant competitors use until 2033.
Pivotal Nasal Antihistamines Manufacturers
Novel Breakthroughs and Advancements
| Company | Glenmark Pharma |
|---|---|
| Strategy | Glenmark Pharma revolutionizes the Indian respiratory market with the affordable nasal spray Ryaltris. |
| Details | In May 2021, Glenmark Pharma launched a nasal spray called Ryaltris in India. Glenmark is one of the market leaders in the respiratory segment and was the first to introduce the branded version at an affordable price in India. |
| Company | Bayer AG |
|---|---|
| Strategy | Bayer's Astepro receive FDA approval for non-prescription use, revolutionizing allergy relief accessibility |
| Details | In June 2021, FDA approved the use of Bayer AG’s Astepro, which is used for seasonal and perineal allergies, for non-prescription use through a process called a partial prescription to nonprescription switch. This approval has led to individuals having the accessibility to a safe and effective nasal antihistamine without requiring the assistance of a healthcare provider. |
| Company | Mylan N.V. |
|---|---|
| Strategy | Mylan and Pfizer Create Viatris Inc., Forming a Global Pharmaceutical Powerhouse |
| Details | In July 2019, Mylan N.V. and Pfizer Inc. signed a definitive agreement to merge Mylan with Upjohn, Pfizer's off-patent branded and generic established pharmaceuticals business, to become Viatris Inc., a new global pharmaceutical corporation. |
| Company | Procter & Gamble (P&G) |
|---|---|
| Strategy | P&G strengthens global presence with €3.4 billion acquisition of Merck's Consumer Health business |
| Details | In December 2018, Procter & Gamble (P&G) completed the acquisition of Merck’s Consumer Health business in a USD 3.8 billion deal. It is intended to improve P&G's over-the-counter (OTC) geographic scale brand portfolio and category footprint across 15 markets. |
The market is valued at USD 2.0 billion in 2023.
Bayer Healthcare, Novartis AG, and Glenmark Pharmaceuticals are key market players.
The market will reach USD 3.2 billion by 2033.
Rising incidence of allergies will drive nasal antihistamines sales.
Nasal sprays are likely to remain preferred through 2033.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product 5.1. Nasal Spray 5.2. Nasal Drops 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Age Group 6.1. Adult 6.2. Pediatric 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Hospital Pharmacies 7.2. Retail Pharmacies 7.3. Drug Stores 7.4. Online Stores 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Western Europe 8.4. Eastern Europe 8.5. South Asia and Pacific 8.6. East Asia 8.7. Middle East and Africa 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. Bayer Healthcare LLC 18.2. Novartis AG 18.3. Glenmark Pharmaceuticals 18.4. GlaxoSmithKline 18.5. Sun Pharmaceuticals 18.6. Cipla 18.7. Merck & Co. 18.8. Viatris (Meda Pharmaceuticals) 18.9. Proctor & Gamble 18.10. Ascend Laboratories LLC (Alkem Laboratories) 18.11. Centaur Pharmaceuticals 18.12. J Pharmaceuticals 18.13. Alitair Pharmaceuticals 18.14. Sato Pharmaceuticals 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Nasal Antihistamines Market
